

22nd URA International Seminar Okayama University

Date: Thursday - (木) 19th September 2024 – Time: 16:30

VENUE: Tsushima Campus – International House

Dominique BAGNARD

(HYBRID mode, broadcasted on ZOOM)

- Biotechnologies – Organoids on a chip - Openings to improved drug testing and to reduction of animal sacrifice

The talk will briefly introduce organoids, with focus on what they are and how they can be fabricated. The seminar will delve into the applications of organoids in drug testing and disease modeling, highlighting the advantages of using organoids over traditional cell cultures and animal models. Moreover, the talk attendees will be taken on board an actual journey into the complexity of these organ-like structures, focusing on the case of cerebroids. From the identification of biomarkers to the use of electron microscopy, the intricate process of developing cerebroids will be discussed in detail.

The seminar will also provide an overview of organoid-on-a-chip technology and its integration in drug discovery, presenting case studies that showcase successful drug development using these technologies.

Future directions and potential challenges in the field will also be discussed, offering a comprehensive understanding of the subject.

NB: The talk is for all audiences including students.

Organized by

Graduate School of Medicine,
Dentistry and Pharmaceutical
Sciences

Organization for Research and
Innovation Strategy

Participation is **free of charge** but **mandatory**.

Advanced Registration - **Deadline: September 14th** :

a - <https://forms.gle/adTpH3iagVCyEq9B6>

b - CC to bernard-chenevier@cc.okayama-u.ac.jp

ZOOM link will be sent to **participants registered outside Okayama**.



https://www.orso.okayama-u.ac.jp/ura_eng/

SPEAKER Short Bio

Professor Dominique Bagnard – Strasbourg University - has been directing an INSERM group research since 2003. As an expert in neurobiology, brain diseases, and neuro-oncology.

He is the Director of Research and Medalis Director at the IMS* Strasbourg Institute for Drug Design and Drug Development.

Pr. Bagnard leads cutting-edge research initiatives in drug discovery and development.

* IMS: <https://ims.unistra.fr/>.

Pr Bagnard also serves as the Dean of the "École Supérieure de Biotechnologie de Strasbourg" (ESBS)**, where he oversees the education and training of future leaders in biotechnology. ESBS is positioned as a premier institution in the field.



** ESBS: <https://esbs.unistra.fr/>,

From the early stages of his career, Pr. Bagnard has been actively involved in scientific publishing. He is the founder and Editor-in-Chief until 2023 of the international journal Cell Adhesion and Migration*** which disseminates critical research findings to the global scientific community.

His entrepreneurial spirit is clearly reflected in the field of technology transfer: he founded two startup companies, Peptimimesis Pharma and Adaptherapy. These ventures companies aim to bring innovative therapies to the marketdemonstrating his commitment to bridging the gap between scientific discovery and clinical applications.

*** <https://www.tandfonline.com/kcam20>

Dominique Bagnard's multifaceted career, spanning academia, research, and entrepreneurship, highlights his strong commitment in advancing global understanding of neurobiology and developing new therapeutic strategies for brain diseases. His work continues to impact the fields of neuro-oncology and biotechnology, fostering innovation and collaboration across disciplines.



[Inquiry]

Bernard CHENEVIER

Senior URA, Okayama University

bernard-chenevier@cc.okayama-u.ac.jp

Ken TAKAHASHI

Professor – Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, – Okayama University

takah-k2@okayama-u.ac.jp